FTO promotes cell proliferation and migration in esophageal squamous cell carcinoma through up-regulation of MMP13
Introduction
Cancer has become a major global menace to human health, and esophageal cancer (EC) is reported to be the seventh leading cause of cancer incidence (572,000 new cases) and the sixth main reason of cancer death (509,000 deaths) according to GLOBOCAN 2018 [1]. The two common histologic subtypes of EC are squamous cell carcinoma (SCC) and adenocarcinoma (AC). There are significant differences between the two types of risk factors, affecting their global distribution[2] In China, esophageal squamous cell carcinoma (ESCC) is the dominate subtype of EC[3,4]. Because ESCC is often accompanied by extensive lymphatic diffusion and vascular invasion, the patients are generally diagnosed at advanced stage[5,6]. Even though lots of studies and experiments have made significant progress in the therapy of ESCC, the patients’ survival rates remain low[2] and our knowledge on ESCC is still very limited. Therefore, it is urgently required to investigate new drug targets and update therapeutic strategies for improving the overall survival of patients with ESCC.
In recent years, more and more evidences have revealed that N6-methyladenosine (m6A) has a large impact on the genesis and development in many cancer types[7]. m6A is an abundant chemical modification of eukaryotic messenger RNA (mRNA). The metabolisms and functions of m6A are controlled by the m6A “writers”, “erasers” and “readers” proteins[[7], [8], [9]]. As methyltransferase, “writers” is mainly composed of METTL3, METTL14 and WTAP, which is responsible for the methylation of m6A[10]. The m6A demethylases FTO and ALKBH5 are known as “erasers”. “Readers” are a class of RNA-binding proteins that interact with, or, are repelled by m6A, such as the YT521-B homology (YTH) domain family proteins that specifically recognize m6A[11,12]. Furthermore, “readers” is a class of important proteins to identify the m6A sites and decides its reversible regulation by YT521-B homology (YTH) domain family[7,13]. Of all the proteins, FTO has been reported to contribute to carcinogenesis in many cancers, including gastric cancer, acute myeloid leukemia and cervical squamous cell carcinoma[[14], [15], [16], [17]]. However, it's unclear whether FTO exerts a tumorigenic role in ESCC as mentioned above.
The aim of this study was to explore the function and expression of FTO in ESCC. The final results demonstrated that FTO expression was increased in ESCC tissues and knockdown of FTO significantly restrained the proliferation and migration of ESCC cells. The next-generation sequencing of the transcriptome indicated that MMP13, an extracellular matrix metalloproteinase, may be a possible downstream target of FTO. These observations will provide new promising therapeutic targets for ESCC.
Section snippets
Cell lines and cultures
Human ESCC cell lines KYSE150, Eca-109 and TE-1 were obtained from cell bank of Chinese academy of Sciences (Shanghai, China). Cell lines were cultured in Dulbecco's modified Eagle's medium (DMEM) with 10% fetal bovine serum and antibiotics (100 μg/mL penicillin and 100 μg/mL streptomycin) at 37 °C in a humidified incubator with 5% CO2.
Human tissue microarray (TMA) and immunohistochemistry (IHC)
The human ESCC tissue microarray (#HEsoS160CS01) was constructed by Shanghai Outdo biotech Co. Ltd, China, which consisting of 80 ESCC tissues and paired
FTO expression is up-regulated in ESCC tissues
In order to explore the expression of FTO in ESCC, a tissue microarray consisting of 80 ESCC tissues and corresponding para-cancerous normal esophagus tissues was subject to immunohistochemistry (IHC) staining. The representative images of IHC were shown in Fig. 1A, and the IHC results revealed that the percentage of FTO positive expression in caner samples was higher than that in adjacent normal tissues (Fig. 1B). Similarly, the data from Gene Expression Profiling Interactive Analysis (GEPIA)
Discussion
m6A modification has acquired substantial progress in the past few years and has been found to be closely connected with human diseases, including cancer. Previous studies have reported that elevated expression of m6A's demethylase FTO was discovered in several types of cancer by immunohistochemical analysis, including breast tumor, lung squamous cell carcinoma, leukemia and gastric cancer[14,15,[18], [19], [20]]. However, the effect of FTO in ESCC is not clarified. In the present work, we
CRediT authorship contribution statement
Shenxiang Liu: Data curation, Formal analysis, Methodology, Writing - original draft, Writing - review & editing. Mei Huang: Methodology, Writing - review & editing. Zhiqin Chen: Formal analysis, Methodology, Writing - review & editing. Jingde Chen: Formal analysis, Writing - review & editing. Qian Chao: Writing - review & editing. Xudong Yin: Investigation, Supervision, Writing - review & editing. Ming Quan: Methodology, Writing - original draft, Writing - review & editing.
Declaration of competing interest
The authors have declared that they have no competing interests.
Acknowledgments
This work was supported by grants from National Natural Science Foundation of China (No. 81972280), Natural Science Foundation of Shanghai (No. 19ZR1441800), Key Disciplines Group Construction Project of Pudong Health Bureau of Shanghai (No. PWZxq2017-13), and Outstanding Clinical Discipline Project of Shanghai Pudong (No. PWYgy2018-02).
References (28)
Mechanism of N(6)-methyladenosine modification and its emerging role in cancer
Pharmacol. Ther.
(2018)- et al.
ALKBH5 is a mammalian RNA demethylase that impacts RNA metabolism and mouse fertility
Mol. Cell.
(2013) - et al.
FTO plays an oncogenic role in acute myeloid leukemia as a N(6)-methyladenosine RNA demethylase
Canc. Cell
(2017) - et al.
The m6A demethylase FTO promotes the growth of lung cancer cells by regulating the m6A level of USP7 mRNA
Biochem. Biophys. Res. Commun.
(2019) - et al.
m(6)A demethylase FTO facilitates tumor progression in lung squamous cell carcinoma by regulating MZF1 expression
Biochem. Biophys. Res. Commun.
(2018) - et al.
Matrix metalloproteinase collagenolysis in health and disease
Biochim. Biophys. Acta Mol. Cell Res.
(2017) - et al.
Moving targets: emerging roles for MMPs in cancer progression and metastasis
Matrix Biol.
(2015) - et al.
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
CA Canc. J. Clin.
(2018) - et al.
Esophageal cancer: risk factors, screening and endoscopic treatment in Western and Eastern countries
World J. Gastroenterol.
(2015) - et al.
Cancer statistics in China, 2015
CA Canc. J. Clin.
(2016)
Cancer incidence and mortality: a cohort study in China, 2008-2013
Int. J. Canc.
BRCA1-Associated protein increases invasiveness of esophageal squamous cell carcinoma
Gastroenterology
Silencing of CXCR2 and CXCR7 protects against esophageal cancer
Am. J. Trans. Res.
N(6)-methyladenosine-dependent RNA structural switches regulate RNA-protein interactions
Nature
Cited by (51)
Evaluation of MMP-13 and Micro RNA-138 as prognostic biomarkers for breast cancer in Egyptian women patients
2024, Pathology Research and PracticeN6-methyladenosine (m6A) methylation in kidney diseases: Mechanisms and therapeutic potential
2023, Biochimica et Biophysica Acta - Gene Regulatory MechanismsThe roles of RNA N<sup>6</sup>-methyladenosine in esophageal cancer
2022, HeliyonCitation Excerpt :FTO is an m6A-modified demethylase that has been associated with various tumours. Liu et al. demonstrated that FTO was upregulated in ESCC tissues and promoted the proliferation and migration of ESCC cells by upregulating MMP13 [59]. FTO can also promote the formation of EC cell lipid droplets by enhancing the expression of HSD17B11, thus promoting EC proliferation, invasion and tumorigenicity [60].
Recent developments in the significant effect of mRNA modification (M6A) in glioblastoma and esophageal cancer
2022, Scientific AfricanCitation Excerpt :In addition, Zhao et al (2021) showed that HNRNPA2B1, IGF2BP2, HNRNPC, VIRMA, HNRNPA2B1 promoted progression in EC and were significantly correlated to worse prognosis in patients with advanced-stage EC [134]. Besides, the M6A demethylase ALKBH5 is an independent prognostic factor and promoter of proliferation in ESCC [151,152]. While FTO has been revealed to promote EC progression through YTHDF1-dependent posttranscriptional silencing of AKT serine/threonine kinase 3 (AKT3) [139].
- 1
Shenxiang Liu, Mei Huang and Zhiqin Chen contributed equally to this work.